SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 16.59-2.7%Sep 20 12:00 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: drtom12344/26/2018 5:30:01 AM
19 Recommendations

Recommended By
captcobra1
CelebrityEquity
corndog
dorightbythem
erippetoe

and 14 more members

   of 52512
 
I think it's important that we understand how important this ASCO presentation is. This year, around 266,000 women in the US will be diagnosed with invasive breast cancer. Only 15% of those will have TNBC, but two thirds of breast cancer is hormone receptor positive. Even if you assume that SG will be used only in cases failing standard therapy, use of SG in this patient population would dramatically increase the potential patient population. And that's just in the U.S; around the world, over 1.7 million women will be diagnosed with breast cancer every year, meaning over 1 million women with hormone receptor positive invasive breast cancer will be potential patients for SG.

Moreover, the fact that this was given an oral presentation spot rather than a simple poster presentation means the ASCO organizers feel that it is a significant piece of research, and needs a larger audience.

If the data is good, and presumably it is based on Immunomedics advertising it with an investor presentation at ASCO, then the company could see large scale off label use after it gets TNBC accelerated approval, and while confirmatory studies are being done.

Basically, "silly" valuation of the company may be closer than previously thought.

Now bring on urothelial breakthrough status!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext